References
- Asao R, Asanuma K, Kodama F, et al. (2012). Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol 7:1385–93.
- Betsholtz C, He L, Takemoto M, et al. (2007). The glomerular transcriptome and proteome. Nephron Exp Nephrol 106:e32–6.
- Hara M, Yamagata K, Tomino Y. (2012). Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia 55:2913–19.
- Hara M, Yanagihara T, Hirayama Y, et al. (2010). Podocyte membrane vesicles in urine originate from tip vesiculation of podocyte microvilli. Hum Pathol 41:1265–75.
- Jha V, Garcia-Garcia G, Iseki K, et al. (2013). Chronic kidney disease: global dimension and perspectives. Lancet 382:260–72.
- Kobayashi K, Yokoh H, Sato Y, et al. (2014). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. Diabetes Obes Metab 16:761–5.
- Lin H, Ye S, Xu J, et al. (2015). The alpha-lipoic acid decreases urinary podocalyxin excretion in type 2 diabetics by inhibiting oxidative stress in vivo. J Diabetes Complications 29:64–7.
- Palacios de Franco Y, Velazquez K, Segovia N, et al. (2015). Urinary podocalyxin as a marker of preeclampsia in a Hispanic population. Int J Physiol Pathophysiol Pharmacol. 12:115–24.
- Sakamoto K, Kuno K, Takemoto M, et al. (2015). Pituitary adenylate cyclase-activating polypeptide protects glomerular podocytes from inflammatory injuries. J Diabetes Res 2015:727152
- Suwanpen C, Nouanthong P, Jaruvongvanich V, et al. (2015). Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity. J Nephrol [Epub ahead of print]. DOI: 10.1007/s40620-015-0199-8
- Takemoto M, Ishikawa T, Onishi S, et al. (2013). Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia. Diabetes Res Clin Pract 100:e26–9.
- Wiggins RC. (2007). The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71:1205–14.
- Yokoh H, Kobayashi K, Sato Y, et al. (2015). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. J Diabetes Investig 6:182–91.